Neurotrope, Inc. (NTRP): Price and Financial Metrics

Neurotrope, Inc. (NTRP): $0.94

-0.11 (-10.48%)

POWR Rating

Component Grades













Add NTRP to Watchlist
Sign Up

Industry: Biotech



in industry

NTRP Stock Price Chart Interactive Chart >

Price chart for NTRP

NTRP Price/Volume Stats

Current price $0.94 52-week high $3.85
Prev. close $1.05 52-week low $0.68
Day low $0.92 Volume 500,200
Day high $1.04 Avg. volume 597,206
50-day MA $1.05 Dividend yield N/A
200-day MA $1.13 Market Cap 22.36M

Neurotrope, Inc. (NTRP) Company Bio

Neurotrope, Inc., a biopharmaceutical company, focuses on developing therapeutic and diagnostic technologies in the field of neurodegenerative diseases in the United States. The company was founded in 2012 and is based in New York City, New York.

NTRP Latest News Stream

Event/Time News Detail
Loading, please wait...

NTRP Latest Social Stream

Loading social stream, please wait...

View Full NTRP Social Stream

Latest NTRP News From Around the Web

Below are the latest news stories about Neurotrope Inc that investors may wish to consider to help them evaluate NTRP as an investment opportunity.

Neurotrope secures supply of Bryostatin-1

Neurotrope (NTRP) inks an agreement with BryoLogyx to supply synthetic Bryostatin-1, manufactured by Albany Molecular Research, for its clinical trials in Alzheimer's disease and other neurodegenerative disorders and commercial use, if approved.BryoLogyx will pay a fee on its gross sales of Bryostatin-1 for the treatment of acute lymphocytic leukemia ((ALL))...

Seeking Alpha | June 10, 2020

BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1

DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1

Business Wire | June 10, 2020

Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia

Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced its entry into a strategic agreement with BryoLogyx Inc.,, for the supply of synthetic, GMP-certified Bryostatin-1, manufactured by Albany Molecular Research, Inc. ("AMRI"), a leading global CDMO provider of advanced drug development and manufacturing solutions. Neurotrope expects to use the synthetic Bryostatin-1 in its clinical development initiatives aimed at advancing its lead product candidate for the treatment of Alzheimer's disease ("AD") and other neurodegenerative diseases and, ultimately, as a source for potential commercial drug supply if regulatory approval is received.

Yahoo | June 10, 2020

Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease

Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The Phase 2 clinical study will be conducted in collaboration with the National Institutes of Health (NIH) under a $2.7 million grant to Neurotrope. After reviewing the data from the previous trial with Key Opinion Leaders and the NIH, we designed a study to evaluate the long-term therapeutic effect of Bryostatin-1 in the absence of Namenda® (memantine) in patients with AD. The Company has engaged Worldwide Clinical Trials to initiate site recruitment and activation.

Yahoo | May 28, 2020

IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - WMGI, MINI, NTRP

NEW YORK, NY / ACCESSWIRE / May 20, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek ...

Yahoo | May 20, 2020

Read More 'NTRP' Stories Here

NTRP Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -19.66%
5-year -86.49%
2022 N/A
2021 N/A
2020 0.00%
2019 -72.49%
2018 -49.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6526 seconds.